Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 13/20 | 0.77 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.73 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.72 |
| ▸ | MMP3 | P08254 | 2/20 | 0.61 |
| ▸ | MMP13 | P45452 | 2/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7144793 | 1.00 | AKR1B1 (0.77) | AKR1B1PTPN1PTPN2MMP3MMP13 | |
| SCHEMBL7145553 | 0.96 | AKR1B1 (0.72) | AKR1B1PTPN1PTPN2MMP3MMP13 | |
| SCHEMBL7145550 | 0.96 | AKR1B1 (0.72) | AKR1B1PTPN1PTPN2MMP3MMP13 | |
| SCHEMBL7146814 | 0.95 | AKR1B1 (0.77) | AKR1B1PTPN1PTPN2 | |
| SCHEMBL7146812 | 0.95 | AKR1B1 (0.77) | AKR1B1PTPN1PTPN2 | |
| SCHEMBL7144830 | 0.94 | AKR1B1 (0.75) | AKR1B1PTPN1PTPN2MMP3MMP13 | |
| SCHEMBL7148334 | 0.92 | POLB (0.68) | AKR1B1PTPN1PTPN2GFER | |
| SCHEMBL7148330 | 0.92 | POLB (0.68) | AKR1B1PTPN1PTPN2GFER | |
| SCHEMBL7143689 | 0.92 | MEN1 (0.74) | AKR1B1PTPN1PTPN2GFERADAMTS5 | |
| SCHEMBL7143685 | 0.92 | MEN1 (0.74) | AKR1B1PTPN1PTPN2GFERADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506755-B2 | 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis | HOFFMANN-LA ROCHE INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020037901-A1 | Thiazolidinecarboxyl acids | HOFFMANN-LA ROCHE INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1189894-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001057006-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037901-A1 | Thiazolidinecarboxyl acids | TPMT, NAT1, THRA | AKR1B1 281/4885PTPN1 312/4885PTPN2 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.